- Home
- XTLB vs EVGN Comparison
XTLB vs EVGN Comparison
Compare XTLB & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTLB
- EVGN
- Stock Information
- Founded
- XTLB 1993
- EVGN 1999
- Country
- XTLB Israel
- EVGN Israel
- Employees
- XTLB N/A
- EVGN N/A
- Industry
- XTLB Biotechnology: Pharmaceutical Preparations
- EVGN Agricultural Chemicals
- Sector
- XTLB Health Care
- EVGN Industrials
- Exchange
- XTLB Nasdaq
- EVGN Nasdaq
- Market Cap
- XTLB 7.8M
- EVGN 9.7M
- IPO Year
- XTLB 2005
- EVGN N/A
- Fundamental
- Price
- XTLB $1.44
- EVGN $1.35
- Analyst Decision
- XTLB
- EVGN Strong Buy
- Analyst Count
- XTLB 0
- EVGN 1
- Target Price
- XTLB N/A
- EVGN $12.00
- AVG Volume (30 Days)
- XTLB 12.8K
- EVGN 58.6K
- Earning Date
- XTLB 02-20-2025
- EVGN 11-21-2024
- Dividend Yield
- XTLB N/A
- EVGN N/A
- EPS Growth
- XTLB N/A
- EVGN N/A
- EPS
- XTLB N/A
- EVGN N/A
- Revenue
- XTLB N/A
- EVGN $7,478,000.00
- Revenue This Year
- XTLB N/A
- EVGN $90.35
- Revenue Next Year
- XTLB N/A
- EVGN $38.71
- P/E Ratio
- XTLB N/A
- EVGN N/A
- Revenue Growth
- XTLB N/A
- EVGN 30.69
- 52 Week Low
- XTLB $0.76
- EVGN $1.20
- 52 Week High
- XTLB $4.99
- EVGN $10.40
- Technical
- Relative Strength Index (RSI)
- XTLB 30.57
- EVGN 36.47
- Support Level
- XTLB $1.42
- EVGN $1.20
- Resistance Level
- XTLB $1.83
- EVGN $1.49
- Average True Range (ATR)
- XTLB 0.12
- EVGN 0.12
- MACD
- XTLB -0.04
- EVGN 0.01
- Stochastic Oscillator
- XTLB 3.13
- EVGN 35.71
About XTLB XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.